Recent studies indicate that the origin of itch in psoriasis (PsO) might involve various mediators like neuropeptides and cytokines, which are similar yet distinct from those in atopic dermatitis (AD), which includes factors like notch signaling. Despite the differences in underlying pathology, both conditions have begun to receive targeted therapies due to advancements in genetic research.
In a comparative analysis of patient-reported outcomes from three phase 3 clinical trials—two for AD and one for PsO—data revealed that both patient groups started with similar itch severities, but patients with AD reported higher impacts on their quality of life. The researchers highlighted the strong correlation between itch severity and life quality improvement, demonstrating the importance of incorporating regular itch assessments in clinical trials and possibly treating itch severity as a primary or secondary endpoint in future studies. The findings also emphasized the necessity of advanced predictive models in understanding and forecasting patient outcomes based on itch severity. This paves the way for tailored treatments that could alleviate the burden of disease more effectively for both patients with PsO and AD.
Reference: Hebebrand M. Study Emphasizes Itch Assessment in PsO and AD Trials. Dermatology Times. Published August 13, 2024. Accessed September 6, 2024. https://www.dermatologytimes.com/view/study-emphasizes-itch-assessment-in-pso-and-ad-trials
Link: https://www.dermatologytimes.com/view/study-emphasizes-itch-assessment-in-pso-and-ad-trials
